January 31st, 2008

SpeculatingStocks.com Stock Pick: Celsion Corporation (CLN)

Stock Price: $5.94

Celsion Corporation is a biotechnology company engaged in the development and commercialization of treatment systems for the treatment of cancer and other diseases in the United States. It develops and commercializes oncology drugs, including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems.

CLN's ThermoDox drug delivery technology is being studied as a first line of treatment of primary liver cancer in combination with radio frequency ablation. The liver cancer Phase III trial using ThermoDux and the company's breast cancer program are on track creating positive, fundamental momentum for CLN.

CLN is trading at a market cap of only around $63.3 million and has a strong balance sheet with cash, cash equivalents, short-term and long-term investments of $26.48 million. CLN has debt of only $500,000 on the balance sheet.

CLN will be moving to the NASDAQ on February 8th from the AMEX. CLN has a strong amount of momentum built into its chart and fundamentals while biotechnology stocks continue to be steady.